Please ensure Javascript is enabled for purposes of website accessibility

3 Most Overvalued Biotech Stocks on the Market Right Now

By Keith Speights and Brian Orelli, PhD – Updated Oct 5, 2021 at 10:30PM

Key Points

  • Moderna's market cap seems outrageous due to the uncertainty of its growth prospects.
  • Beam Therapeutics' valuation is sky-high with no clinical-stage candidates yet.
  • CureVac looks way too expensive considering questions about the efficacy of its COVID vaccine candidate.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are paying through the nose for these stocks.

Assessing the value of biotech stocks can be difficult. There are lots of variables, including pipeline prospects and market dynamics. But some biotech stocks trade at prices that seem to be at nosebleed levels. In this Motley Fool Live video recorded on Sept. 22, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss three biotech stocks that appear to be the most overvalued right now.

10 stocks we like better than Moderna Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of September 17, 2021


Keith Speights: Now, let's switch to a non-newsy topic here. We talk quite often about biotech stocks that we like. Let's go the other direction though, Brian. If you had to pick the three most overvalued biotech stocks on the market right now, which ones would you choose?

Brian Orelli: Value is in the eye of the beholder, and obviously, there are people buying at the current valuation. Obviously, there are people with whatever the three stocks, I'm going to mentioned, there are people who think that the value is perfectly acceptable right now because they are buying it that level.

But the three I would go with was Moderna (MRNA -3.98%), the market caps around $175 billion. It trades at about 8.6 times 2021 potential sales of $20 billion. That's not bad if it was growing. But we'll just have to wait and see how long we'll need the boosters, and then how much competition the company gets. I don't know, I just feel like $175 billion for $20 billion in sales is a little outrageous. That's mostly a valuation play.

Beam Therapeutics (BEAM -5.75%) is another company I have a bit of a valuation issue with. I like the company. I like the technology. It's using CRISPR to make single-based changes in its genome. But it's valued around $6.6 billion. But it hasn't even started clinical trial yet.

So $6.6 billion for promising but unproven technology seems like it's a little high. I'm not going to say it won't go up from here, but it's certainly worth much more if it can prove the technology works. But I'm not sure that the upside really justifies the unknown risks.

If you look at something like CRISPR Therapeutics, its market cap is $8.9 billion, and Intellia is $11.3 billion, and they at least have clinical trial data that have shown that there is proof of concept data to show that their drugs work, where Beam Therapeutics is at $6.6 billion, but hasn't actually proven in the clinic that they can show that their drug works.

Then the third one I would say is CureVac (CVAC -1.48%). Ticker there is CVAC. Its market cap is $11.3 billion. Has an mRNA COVID-19 vaccine. But it doesn't seem like it's actually working. The efficacy was only about 48 percent in the 90 percent range for Moderna and Pfizer's mRNA vaccines. The company highlighted the increase in variants when the Phase III clinical trial was ran. They ran their clinical trial much later than Moderna and Pfizer, and they think that might be the reason for the lower efficacy.

But I think the bigger issue might just be the dose wasn't high enough. They tested a higher dose in Phase I, but the side effects were too strong until they decided to go with a lower dose. Their lower dose doesn't really create the same level of antibodies as Moderna's, and Pfizer, and BioNTech's.

I think that's probably the bigger issue and the reason why the vaccine doesn't work. Then if that vaccine doesn't work at the lower dose and the higher dose has too higher of the side effects, then that could mean that they use a different mRNA technology compared to Moderna and BioNTech's. I'm a little worried that their whole technology doesn't work, and if that's the reason, then it's hard to justify the $11.3 billion on their pipeline if their pipeline is going to work because their technology doesn't work.

Editor's note: The original transcript stated CureVac's efficacy was about 47%. The actual efficacy was 48%. 

Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
$177.35 (-3.98%) $-7.35
Pfizer Stock Quote
$51.72 (-0.12%) $0.06
Intellia Therapeutics Stock Quote
Intellia Therapeutics
$37.94 (-1.07%) $0.41
CRISPR Stock Quote
$48.99 (-2.99%) $-1.51
Beam Therapeutics Stock Quote
Beam Therapeutics
$42.12 (-5.75%) $-2.57
BioNTech Se Stock Quote
BioNTech Se
$170.30 (-0.88%) $-1.51
CureVac  Stock Quote
$7.98 (-1.48%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.